CCO Official Conference Coverage
|
2009 Annual Meeting of the American Association for the Study of Liver Diseases*
October 30-November 3, 2009 | Boston, Massachusetts
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Choose from 2 tracks of coverage (mouse over track for more info)
|
CME-Certified Expert Analysis
|
|
|
PREVIEW OTHER ANALYSES:
TRACK 1 |
TRACK 2
|
CCO Slideset
Highlights From AASLD 2009
 |
|
Review the most clinically relevant new data from the 2009 AASLD conference on HCV, HBV, and complications of advanced liver disease.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.09 MB
| Date posted: 11/17/2009
|
Expert Highlights
Disclosures – Audio Expert Highlights
Robert S. Brown Jr., MD, MPH, has disclosed that he has received consulting fees from Gilead Sciences and Schering-Plough; fees for non-CME/CE services from Gilead Sciences, Roche Pharmaceuticals, and Schering-Plough; and contracted research from Bristol-Myers Squibb, Gilead Sciences, Salix, Schering-Plough, and Vertex.
Peter Ferenci, MD, has disclosed that he has received consulting fees from HGS, Madaus Pharmaceuticals, Novartis, Roche, Tibotec, and Vertex; fees for non-CME/CE services from Roche; and contracted research from Boehringer Ingelheim, Roche, and Tibotec.
Anna S. F. Lok, MD, has disclosed that she has received grants or research support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Roche, and Schering-Plough and has served as a consultant for Bayer, Bristol-Myers Squibb, Gilead Sciences, and Roche.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
A2ALL Interim Analysis: Virologic Response 12 Weeks After Liver Transplantation Feasible With Pretransplantation Peginterferon alfa-2b/Ribavirin Therapy
Although pre–liver transplantation peginterferon alfa-2b/ribavirin effectively prevented HCV recurrence posttransplantation in a subset of patients, serious adverse event rates were higher among patients who received peginterferon/ribavirin therapy prior to liver transplantation relative to patients who did not receive pretransplantation therapy.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|